Veracyte, CareDx partner for transplant rejection testing

By staff writers

May 15, 2020 -- CareDx will become the exclusive commercialization partner for solid organ transplant rejection tests that run on Veracyte's nCounter Flex Analysis System diagnostic platform.

In September 2019, CareDx announced plans to develop a gene expression profiling system to identify allograft rejection in transplant biopsy tissue. The resulting HistoMap technology will run on Veracyte's platform and include the Human Organ Transplant panel from the Banff Foundation for Allograft Pathology.

The partnership is Veracyte's first with a diagnostic company. CareDx will be responsible for the test's global commercialization.

Veracyte licenses gene signature for idiopathic pulmonary fibrosis
Veracyte has licensed exclusive rights to a 52-gene signature for idiopathic pulmonary fibrosis from Yale University and plans to develop a blood test...
Veracyte licenses NanoString diagnostic platform in $50M deal
Veracyte is set to pay $50 million -- $40 million in cash and the rest in common stock -- for an exclusive global license to the NanoString...
Veracyte nasal swab test holds its own in lung cancer detection
Veracyte said the accuracy of its investigational nasal swab genomic classifying test rivals the clinical standard for lung nodule assessment and has...
Veracyte validates Afirma XA in thyroid cancer
Veracyte published data in Frontiers in Endocrinology on September 11 supporting the utility of its Afirma Expression Atlas (XA) test for identifying...
Popular rule-out test for thyroid cancer draws scrutiny
Researchers are questioning whether a commonly used gene expression classifier test for evaluating indeterminate thyroid nodules lives up to expectations,...

Copyright © 2020

Last Updated ls 5/14/2020 4:09:07 PM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.